Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 16;7:1993. doi: 10.1038/s41598-017-02068-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

FGFR4 blockade inhibits the progression of LVH in the 5/6 nephrectomy rat model of CKD. (a–c) Cardiac parameters of 5/6 nephrectomized rats were evaluated by echocardiography at baseline, four weeks (pre) and eight weeks after surgery (post). All 5/6 nephrectomized animals develop LVH four weeks post-surgery, but anti-FGFR4 treatment prevents the progression of cardiac remodeling when compared to vehicle-treated rats. (d) Representative images of WGA-stainings of the LV free wall (original magnification x63, scale bar 70 µm). (e) Cross-sectional area of 25 myocytes per field of 4 fields along the LV free wall. (f) Representative Picrosirius Red stainings of the LV free wall (original magnification x20, scale bar 100 µm). (g) Quantification of myocardial fibrosis based on positive Picrosirius Red labeling (8 fields of view around the LV). (h,i,j) Quantitative real-time PCR analysis of cardiac tissue using GAPDH as a house keeping gene. mRNA levels of hypertrophic markers (BNP, β-MHC) and the NFAT target gene RCAN1 are significantly decreased in anti-FGFR4 treated rats when compared to vehicle-injected animals. Fibrosis markers (Col1a1, Timp) and the NFAT target gene TRPC6 show a trend towards a decrease upon FGFR4 blockade (p = 0.0593). (k,l,m) Cardiac function remains unchanged upon induction of CKD as well as before and after administration of anti-FGFR4. No significant differences were found in ejection fraction, fractional shortening and cardiac output over time. All values are mean ± SEM (n = 6–8 per group; *p < 0.05).